Comera Life Sciences Holdings, Inc. (CMRA)
OTCMKTS: CMRA · Delayed Price · USD
0.0410
0.00 (0.00%)
Apr 18, 2024, 1:09 PM EDT - Market open
Company Description
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform.
Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions.
The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Comera Life Sciences Holdings, Inc.
| Country | MA |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Michael G. Campbell CPA |
Contact Details
Address: 12 Gill Street, Suite 4650 Woburn, Massachusetts 01801 United States | |
| Phone | (617)871-2101 |
| Website | comeralifesciences.com |
Stock Details
| Ticker Symbol | CMRA |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001907685 |
| CUSIP Number | 20037C108 |
| ISIN Number | US20037C1080 |
| Employer ID | 87-4706968 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael G. Campbell CPA | Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer |
| Dr. David Soane Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Janice Marie McCourt B.S., CLP, M.B.A., R.Ph. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2024 | EFFECT | Notice of Effectiveness |
| Feb 27, 2024 | EFFECT | Notice of Effectiveness |
| Feb 27, 2024 | EFFECT | Notice of Effectiveness |
| Feb 27, 2024 | EFFECT | Notice of Effectiveness |
| Feb 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 26, 2024 | POS AM | Post-Effective amendments for registration statement |
| Feb 26, 2024 | POS AM | Post-Effective amendments for registration statement |
| Feb 26, 2024 | POS AM | Post-Effective amendments for registration statement |